We are live on ! Find out more
P

Pfizer Portfolio holdings

AUM $170M
1-Year Est. Return 191.09%
This Fund
S&P 500
This Quarter Est. Return
+6.77%
1 Year Est. Return
+191.09%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$170M
AUM Growth
-$68.4M
Cap. Flow
-$52.5M
Cap. Flow %
-30.79%
Top 10 Hldgs %
95.78%
Holding
18
New
–
Increased
–
Reduced
3
Closed
1

Top Buys

No buys this quarter

Top Sells

Rank Stock Value
1
ORIC icon
Oric Pharmaceuticals
ORIC
+$40M
2
ZURA icon
Zura Bio
ZURA
+$11M
3
NXTC icon
NextCure
NXTC
+$806K
4
QTTB icon
Q32 Bio
QTTB
+$737K

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ALLO icon
1
Allogene Therapeutics
ALLO
$684M
$46.9M 27.55%
22,032,040
– –
CELC icon
2
Celcuity
CELC
$4.67B
$29.6M 17.35%
295,652
– –
ARVN icon
3
Arvinas
ARVN
$611M
$27.7M 16.24%
3,457,815
– –
PYXS icon
4
Pyxis Oncology
PYXS
$319M
$19.5M 11.43%
7,032,770
– –
WVE icon
5
Wave Life Sciences
WVE
$928M
$10.9M 6.42%
1,875,000
– –
BHVN icon
6
Biohaven
BHVN
$2.34B
$8M 4.7%
505,645
– –
CRBU icon
7
Caribou Biosciences
CRBU
$168M
$7.88M 4.63%
4,690,431
– –
SPRO icon
8
Spero Therapeutics
SPRO
$69.3M
$5.34M 3.13%
2,362,348
– –
ZNTL icon
9
Zentalis Pharmaceuticals
ZNTL
$383M
$3.85M 2.26%
953,834
– –
ORIC icon
10
Oric Pharmaceuticals
ORIC
$1.31B
$3.55M 2.09%
372,904
-4,407,497
-92% -$40M
CRDF icon
11
Cardiff Oncology
CRDF
$84.8M
$3.01M 1.77%
2,411,575
– –
ZURA icon
12
Zura Bio
ZURA
$560M
$2.88M 1.69%
538,841
-2,300,072
-81% -$11M
AGMB
13
AgomAb Therapeutics NV
AGMB
$720M
$1.04M 0.61%
75,000
– –
BOLT icon
14
Bolt Biotherapeutics
BOLT
$7.51M
$134K 0.08%
31,305
– –
NXTC icon
15
NextCure
NXTC
$35.3M
$73K 0.04%
44,347
-109,007
-71% -$806K
DNA icon
16
Ginkgo Bioworks
DNA
$461M
$30K 0.02%
2,928
– –
SENS icon
17
Senseonics Holdings Inc
SENS
$519M
$12.4K 0.01%
2,171
– –
QTTB icon
18
Q32 Bio
QTTB
$356M
– –
-101,618
Closed -$737K

Similar funds

BDS
Banco de Sabadell Miami, Florida $170M AUM 26.61% 1-Year Est. Return
WBCM
Wilson & Boucher Capital Management Moraga, California $170M AUM 28.6% 1-Year Est. Return
NL
NDWM LLC La Jolla, California $170M AUM 17.06% 1-Year Est. Return
CPA
Cathy Pareto & Associates Coral Gables, Florida $171M AUM 25.52% 1-Year Est. Return
IIM
Invariant Investment Management Camp Hill, Pennsylvania $171M AUM
WA
WPG Advisers Baltimore, Maryland $170M AUM 33.45% 1-Year Est. Return
EWM
Evolution Wealth Management Fort Myers, Florida $170M AUM 19.89% 1-Year Est. Return
HP
Harbourvest Partners Boston, Massachusetts $170M AUM 34.45% 1-Year Est. Return

Pfizer's Q2 2026 Portfolio in Review

As of Q2 2026, Pfizer held 18 positions worth $170M, down 29% from $239M the previous quarter. Its ten largest holdings account for 96% of the portfolio.

Pfizer withdrew a net $52.5M in Q2 2026, closing 1 position and reducing 3 holdings. Its most notable exit was Q32 Bio, an estimated $737K position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

  • Pfizer's biggest Q2 2026 reduction was Oric Pharmaceuticals, cutting an estimated $40M.
  • Pfizer fully exited Q32 Bio in Q2 2026, selling an estimated $737K.
  • Pfizer's ten largest holdings make up 96% of its $170M portfolio in Q2 2026.
  • Pfizer opened 0 new positions and closed 1 in Q2 2026.
  • Pfizer's portfolio value fell 29% quarter-over-quarter to $170M.

Based on Pfizer's 13F filing for Q2 2026, filed 13 Aug 2026.